These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 30805888

  • 1. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy.
    Oral EA, Gorden P, Cochran E, Araújo-Vilar D, Savage DB, Long A, Fine G, Salinardi T, Brown RJ.
    Endocrine; 2019 Jun; 64(3):500-511. PubMed ID: 30805888
    [Abstract] [Full Text] [Related]

  • 2. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
    Brown RJ, Oral EA, Cochran E, Araújo-Vilar D, Savage DB, Long A, Fine G, Salinardi T, Gorden P.
    Endocrine; 2018 Jun; 60(3):479-489. PubMed ID: 29644599
    [Abstract] [Full Text] [Related]

  • 3. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
    Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, Gorden P.
    Endocr Pract; 2011 Jun; 17(6):922-32. PubMed ID: 22068254
    [Abstract] [Full Text] [Related]

  • 4. Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance.
    Lambadiari V, Kountouri A, Maratou E, Liatis S, Dimitriadis GD, Karpe F.
    Front Endocrinol (Lausanne); 2021 Jun; 12():684182. PubMed ID: 34168618
    [Abstract] [Full Text] [Related]

  • 5. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
    Diker-Cohen T, Cochran E, Gorden P, Brown RJ.
    J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants.
    Sekizkardes H, Cochran E, Malandrino N, Garg A, Brown RJ.
    J Clin Endocrinol Metab; 2019 Aug 01; 104(8):3068-3076. PubMed ID: 31194872
    [Abstract] [Full Text] [Related]

  • 7. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
    Brown RJ, Meehan CA, Cochran E, Rother KI, Kleiner DE, Walter M, Gorden P.
    J Clin Endocrinol Metab; 2017 May 01; 102(5):1511-1519. PubMed ID: 28324110
    [Abstract] [Full Text] [Related]

  • 8. Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use.
    Adamski K, Cook K, Gupta D, Morris E, Tuttle E, Carr E, Cremasco F, Cochran E, Brown RJ.
    Curr Med Res Opin; 2021 Nov 01; 37(11):1881-1889. PubMed ID: 34490811
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.
    Ajluni N, Dar M, Xu J, Neidert AH, Oral EA.
    J Diabetes Metab; 2016 Mar 01; 7(3):. PubMed ID: 27642538
    [Abstract] [Full Text] [Related]

  • 10. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
    Araujo-Vilar D, Sánchez-Iglesias S, Guillín-Amarelle C, Castro A, Lage M, Pazos M, Rial JM, Blasco J, Guillén-Navarro E, Domingo-Jiménez R, del Campo MR, González-Méndez B, Casanueva FF.
    Endocrine; 2015 May 01; 49(1):139-47. PubMed ID: 25367549
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
    Mosbah H, Vantyghem MC, Nobécourt E, Andreelli F, Archambeaud F, Bismuth E, Briet C, Cartigny M, Chevalier B, Donadille B, Daguenel A, Fichet M, Gautier JF, Janmaat S, Jéru I, Legagneur C, Leguier L, Maitre J, Mongeois E, Poitou C, Renard E, Reznik Y, Spiteri A, Travert F, Vergès B, Zammouri J, Vigouroux C, Vatier C.
    Diabetes Obes Metab; 2022 Aug 01; 24(8):1565-1577. PubMed ID: 35445532
    [Abstract] [Full Text] [Related]

  • 12. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.
    Simha V, Subramanyam L, Szczepaniak L, Quittner C, Adams-Huet B, Snell P, Garg A.
    J Clin Endocrinol Metab; 2012 Mar 01; 97(3):785-92. PubMed ID: 22170723
    [Abstract] [Full Text] [Related]

  • 13. One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes.
    Vatier C, Fetita S, Boudou P, Tchankou C, Deville L, Riveline J, Young J, Mathivon L, Travert F, Morin D, Cahen J, Lascols O, Andreelli F, Reznik Y, Mongeois E, Madelaine I, Vantyghem M, Gautier J, Vigouroux C.
    Diabetes Obes Metab; 2016 Jul 01; 18(7):693-7. PubMed ID: 26584826
    [Abstract] [Full Text] [Related]

  • 14. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.
    Park JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, Gorden P.
    J Clin Endocrinol Metab; 2008 Jan 01; 93(1):26-31. PubMed ID: 17940115
    [Abstract] [Full Text] [Related]

  • 15. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
    Nagayama A, Ashida K, Watanabe M, Moritaka K, Sonezaki A, Kitajima Y, Takahashi H, Yoshinobu S, Iwata S, Yasuda J, Hasuzawa N, Ozono S, Motomura S, Nomura M.
    Front Endocrinol (Lausanne); 2021 Jan 01; 12():690996. PubMed ID: 34135866
    [Abstract] [Full Text] [Related]

  • 16. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
    Brown RJ, Valencia A, Startzell M, Cochran E, Walter PJ, Garraffo HM, Cai H, Gharib AM, Ouwerkerk R, Courville AB, Bernstein S, Brychta RJ, Chen KY, Walter M, Auh S, Gorden P.
    J Clin Invest; 2018 Aug 01; 128(8):3504-3516. PubMed ID: 29723161
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
    Chan JL, Koda J, Heilig JS, Cochran EK, Gorden P, Oral EA, Brown RJ.
    Clin Endocrinol (Oxf); 2016 Jul 01; 85(1):137-49. PubMed ID: 26589105
    [Abstract] [Full Text] [Related]

  • 18. A case of generalized lipodystrophy-associated progeroid syndrome treated by leptin replacement with short and long-term monitoring of the metabolic and endocrine profiles.
    Fukaishi T, Minami I, Masuda S, Miyachi Y, Tsujimoto K, Izumiyama H, Hashimoto K, Yoshida M, Takahashi S, Kashimada K, Morio T, Kosaki K, Maezawa Y, Yokote K, Yoshimoto T, Yamada T.
    Endocr J; 2020 Feb 28; 67(2):211-218. PubMed ID: 31708526
    [Abstract] [Full Text] [Related]

  • 19. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.
    Nguyen ML, Sachdev V, Burklow TR, Li W, Startzell M, Auh S, Brown RJ.
    J Clin Endocrinol Metab; 2021 Oct 21; 106(11):e4327-e4339. PubMed ID: 34223895
    [Abstract] [Full Text] [Related]

  • 20. Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.
    Foss-Freitas MC, Akinci B, Neidert A, Bartlett VJ, Hurh E, Karwatowska-Prokopczuk E, Oral EA.
    Lipids Health Dis; 2021 Dec 05; 20(1):174. PubMed ID: 34865644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.